Drug intelligence / Profile preview

LB-04

Development stage: Preclinical
Lead developer: LexBio Therapeutics
Modality: Small Molecules

Overview

LB-04 is a preclinical-stage small molecule therapeutic candidate being developed by LexBio Therapeutics for the treatment of inflammatory and immunological diseases. Currently in the lead optimization phase, the program is part of LexBio's pipeline focused on high-selectivity modulators for autoimmune conditions. The specific biological target and molecular mechanism of action for LB-04 have not yet been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on LB-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB-04.

Explore the full profile